Wcm Investment Management Adds $908M in Teva Pharmaceutical Industries Limited ($TEVA)
Key Points
- Wcm Investment Management changed its Teva Pharmaceutical Industries Limited ($TEVA) stake by 191.43% last quarter, boosting to 40,820,600 shares worth $1.38 billion.
- Wall Street's consensus rating on $TEVA is Strong Buy and an average price target of $41.40.
- $TEVA last traded around $33.88.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Wcm Investment Management increased its position in Teva Pharmaceutical Industries Limited ($TEVA) by 191.43% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,820,600 shares of Teva Pharmaceutical Industries Limited after buying 26,813,522 shares during the quarter. Wcm Investment Management's holdings in Teva Pharmaceutical Industries Limited were worth $1.38 billion as of its most recent filing.
Teva Pharmaceutical Industries Limited Stock Down 7.0%
Shares of Teva Pharmaceutical Industries Limited ($TEVA) traded around $33.88 on Saturday, down 7.0% for the day.
Teva Pharmaceutical Industries Limited Earnings
Analysts Set New Price Targets
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Get Teva Pharmaceutical Industries Limited alerts
New 13F filings, insider trades, and analyst moves on $TEVA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.